Dr. Steven Shnyder

Associate Professor

Area: School of Pharmacy & Medical Sciences; Faculty of Life Sciences
E-mail: S.D.Shnyder@bradford.ac.uk
Phone: +441274235898

Biography

Dr Steve Shnyder is a Senior Lecturer in Cancer Biology at the ICT. He has thirty-five years’ experience as a research scientist: 30 years post-doctoral, 18 months in a start-up pharma, with the past 24 years in a preclinical cancer pharmacology environment at Bradford. He has over 30 years’ experience of working with small mammals, mainly in the preclinical cancer pharmacology field. In his current position he is a Home Office Project and Personal Licence holder and is involved in the management and practical execution of Research and Knowledge Transfer in vivo and in vitro studies carried out at the ICT, working with both UK-based and international clients. His team has contributed to the screening packages of several novel anti-cancer compounds which have subsequently progressed to clinical trials and beyond, using both cell-based and in vivo technologies. He is an author on 80+ journal articles and numerous conference publications as well as four book chapters on in vivo methodology. In addition he has significant experience in the areas of histopathology, biochemistry and cell biology. He line manages a Research Associate whose focus is in vivo studies, and a Research Technician whose focus is in vitro screening. He is a strong proponent of 3Rs philosophy, always striving to apply the 3Rs to all the work he does, and he has been a co-investigator on 2 project grants and a studentship specifically aimed at improving methodology in preclinical cancer pharmacology from a 3Rs standpoint. Aside from this, his main research interests are focused around identifying mechanisms of drug resistance in colorectal cancer.

Research

Characterisation of the reticuloplasmins as anticancer drug targets. Pharmacology of vascular disrupting agents. Development of 3Rs methodologies. Exploitation of the fluorescent properties of anti-cancer therapeutics for utilisation in assessment of pharmacodynamic and pharmacokinetic end-points. Evaluation of the drugability of the tumour cell glycocalyx. Research Team Patricia Cooper, Experimental Officer Gary Lawson, Research Technician Marcella Sini, YCR Programme Grant Postdoctoral Researcher (with L Patterson, P Loadman, R Falconer & K Pors)

Professional activities

British Society of Cell Biology (BSCB)
British Association of Cancer Research (BACR)

Bradford - BSc
Bradford - MPhil
London - PhD

Publications

Oncology Activity

Gill J.;Shnyder S. (2015) Drug Discovery and Evaluation: Pharmacological Assay, Fourth Edition. Springer. 4157-4200.

A non-invasive 2D digital imaging method for detection of surface lesions using machine learning

Hussain N.;Cooper P.;Shnyder S.;Ugail H.;Bukar A.;Connah D. (2017) Proceedings - 2017 International Conference on Cyberworlds, CW 2017 - in cooperation with: Eurographics Association International Federation for Information Processing ACM SIGGRAPH. 2017-January, 166-169.

A Proteomic Investigation to Discover Candidate Proteins Involved in Novel Mechanisms of 5-Fluorouracil Resistance in Colorectal Cancer

Mario Ortega Duran, Sadr ul Shaheed , Christopher W. Sutton and Steven D. Shnyder (2024) Cells. 13
Synthesis and Biological Evaluation of Cyclobutane-Based β3 Integrin Antagonists: A Novel Approach to Targeting Integrins for Cancer Therapy

Mark Sutherland, Andrew Gordon, Fatemah OFO Al-Shammari, Adam Throup, Amy Cilia La Corte, Helen Philippou, Steven D Shnyder, Laurence H Patterson, Helen M Sheldrake (2023) Cancers. 15
Semi-Synthetic Analogues of Cryptolepine as a Potential Source of Sustainable Drugs for the Treatment of Malaria, Human African Trypanosomiasis and Cancer

Abacha, YZ; Donkor Forkuo, A; Gbedema, SY; Mittal, N; Ottilie, S; Rocamora, F; Winzeler, EA; van Schalkwyk, DA; Kelly, JM; Taylor, MC; Reader, J; Birkholtz, L-M; Lisgarten, DR; Cockcroft, JK; Lisgarten, JN; Palmer, RA; Talbert, RC; Shnyder, SD, Wright, CW (2022) Frontiers in Pharmacology. 13
The role of MT1-MMP in the progression and metastasis of osteosarcoma

Spencer, H.L.M.; Shnyder, S.D.; Loadman, P.M.; Falconer, R.A. (2022) Journal of Cancer Metastasis and Treatment. 9
Probing cytochrome P450 (CYP) bioactivation with chloromethylindoline bioprecursors derived from the duocarmycin family of compounds

Natalia Ortuzar, Kersti Karu, Daniela Presa, Goreti R. Morais, Helen M. Sheldrake, Steve D. Shnyder, Francis M. Barnieh, Paul M. Loadman, Laurence H. Patterson, Klaus Pors, Mark Searcey (2021) BIOORGANIC & MEDICINAL CHEMISTRY. 40
Cytochrome P450 isoforms 1A1, 1B1 AND 2W1 as targets for therapeutic intervention in head and neck cancer.

Presa D;Khurram SA;Zubir AZA;Smarakan S;Cooper PA;Morais GR;Sadiq M;Sutherland M;Loadman PM;McCaul J;Shnyder SD;Patterson LH;Pors K; (2021) Scientific Reports. 11
An assay for quantitative analysis of polysialic acid expression in cancer cells

Guo, X.; Elkashef, S.M.; Patel, A.; Ribeiro Morais, G.; Shnyder S.D.; Loadman, P.M.; Patterson, L.H.; Falconer, R.A. (2021) Carbohydrate Polymers. 259
Probing cytochrome P450 (CYP) bioactivation with chloromethylindoline bioprecursors derived from the duocarmycin family of compounds.

Ortuzar N;Karu K;Presa D;Morais GR;Sheldrake HM;Shnyder SD;Barnieh FM;Loadman PM;Patterson LH;Pors K;Searcey M; (2021) Bioorganic and Medicinal Chemistry. 40
Application of Small Molecule FPR1 Antagonists in the Treatment of Cancers

Djevdet S. Ahmet, Haneen A. Basheer, Anwar Salem, Di Lu, Amin Aghamohammadi, Patrick Weyerhäuser, Andrea Bordiga, Juman Almeniawi, Sabah Rashid, Patricia A. Cooper, Steven D. Shnyder, Victoria Vinader, and Kamyar Afarinkia (2020) Scientific Reports. na
Preclinical Anticancer Activity of an Electron-Deficient Organoruthenium(II) Complex

Soldevila-Barreda J.J.;Azmanova M.;Pitto-Barry A.;Cooper P.A.;Shnyder S.D.;Barry N.P.E. (2020) ChemMedChem.
An efficient assay for identification and quantitative evaluation of potential polysialyltransferase inhibitors.

Guo X; Malcolm J.R.; Ali M.M.; Ribeiro Morais G; Shnyder S.D.; Loadman P.M.; Patterson L.H.; Falconer R.A. (2020) ANALYST (PRINT). 145, 4512-4521.
Tumor growth suppression using a combination of taxol-based therapy and GSK3 inhibition in non-small cell lung cancer

O'Flaherty, L.; Shnyder, Steven D.; Cooper, Patricia A.; Cross, S.J.; Wakefield, J.G.; Pardo, O.E.; Seckl, M.J.; Tavare, J.M. (2019)
Hypoxia modulates CCR7 expression in head and neck cancers

Basheer, Haneen A.; Pakanavicius, E.; Cooper, Patricia A.; Shnyder, Steven D.; Martin, L.; Hunter, K.D.; Vinader, Victoria; Afarinkia, Kamyar (2018)
Tubulin-binding dibenz[c,e]oxepines: Part 2.¹Structural variation and biological evaluation as tumour vasculature disrupting agents

Rossington S.;Hadfield J.;Shnyder S.;Wallace T.;Williams K. (2017) Bioorganic and Medicinal Chemistry. 25, 1630-1642.
Preclinical anti-cancer activity and multiple mechanisms of action of a cationic silver complex bearing N-heterocyclic carbene ligands

Allison, Simon J.; Sadiq, Maria; Baronou, Efstathia; Cooper, Patricia A.; Dunnill, C.; Georgopoulos, N.T.; Latif, A.; Shepherd, S.L.; Shnyder, Steven D.; Stratford, I.J.; Wheelhouse, Richard T.; Willans, C.; Phillips, Roger M. (2017) Cancer Letters. 397
Tubulin-binding dibenz[c,e]oxepines. Part 2. 1 Structural variation and biological evaluation as tumour vasculature disrupting agents

Rossington, S.B.; Hadfield, J.A.; Shnyder, Steven D.; Wallace, T.W.; Williams, K.J. (2017)
RGD-Binding Integrins in Head and Neck Cancers

Ahmedah, H.T.; Patterson, Laurence H.; Shnyder, Steven D.; Sheldrake, Helen M. (2017)
Agarose Spot as a Comparative Method for in situ Analysis of Simultaneous Chemotactic Responses to Multiple Chemokines

Ahmed, Mohaned S.A.; Basheer, Haneen A.; Ayuso, J.M.; Ahmet, Djevdet; Mazzini, Marco; Patel, Roshan; Shnyder, Steven D.; Vinader, Victoria; Afarinkia, Kamyar (2017)
The use of thermographic imaging to evaluate therapeutic response in human tumour xenograft models

Hussain, Nosheen; Connah, David; Ugail, Hassan; Cooper, Patricia A.; Falconer, Robert A.; Patterson, Laurence H.; Shnyder, Steven D. (2016) Scientific Reports. 6
The Effect of Polysialic Acid Expression on Glioma Cell Nano-mechanics

Grant, Colin A.; Twigg, Peter C.; Saeed, Rida F.; Lawson, G.; Falconer, Robert A.; Shnyder, Steven D. (2016) BioNanoScience. 6, 81-84.
PIK3CA dependence and sensitivity to therapeutic targeting in urothelial carcinoma

Ross, R.L.; McPherson, H.R.; Kettlewell, L.; Shnyder, Steven D.; Hurst, C.D.; Alder, O.; Knowles, M.A. (2016)
Probing cytochrome P450-mediated activation with a truncated azinomycin analogue

Vinader, Victoria; Sadiq, Maria; Sutherland, Mark H.; Huang, M.Y.; Loadman, Paul M.; Elsalem, Lina M.I.; Shnyder, Steven D.; Cui, H.J.; Afarinkia, Kamyar; Searcey, M.; Patterson, Laurence H.; Pors, Klaus (2015) MedChemComm. 6, 187-191.
Thin-layer chromatography/matrix-assisted laser desorption/ionisation mass spectrometry and matrix-assisted laser desorption/ionisation mass spectrometry imaging for the analysis of phospholipids in LS174T colorectal adenocarcinoma xenografts treated with the vascular disrupting agent DMXAA

Batubara, A.; Carolan, V.A.; Loadman, Paul M.; Sutton, Chris W.; Shnyder, Steven D.; Clench, M.R. (2015) Rapid Communications In Mass Spectrometry. 29, 1288-1296.
Study of the chemotactic response of multicellular spheroids in a microfluidic device

Ayuso, J.M.; Basheer, Haneen A.; Monge, R.; Sánchez-Álvarez, P.; Doblare, M.; Shnyder, Steven D.; Vinader, Victoria; Afarinkia, Kamyar; Fernandez, L.J.; Ochoa, I. (2015)
Potent organometallic osmium compounds induce mitochondria-mediated apoptosis and S-phase cell cycle arrest in A549 non-small cell lung cancer cells

van Rijt, S.H.; Romero-Canelón, I.; Fu, Y.; Shnyder, Steven D.; Sadler, P.J. (2014)
Tumor-Targeted Prodrug ICT2588 Demonstrates Therapeutic Activity Against Solid Tumors and Reduced Potential For Cardiovascular Toxicity

Gill, Jason H.; Loadman, Paul M.; Shnyder, Steven D.; Cooper, Patricia A.; Atkinson, Jennifer M.; Ribeiro Morais, Goreti; Patterson, Laurence H.; Falconer, Robert A. (2014) Molecular Cancer Therapeutics. 11, 1294-1300.
Pharmacological Inhibition of polysialyltransferase ST8SiaII Modulates Tumour Cell Migration

Al-Saraireh, Yousef M.J.; Sutherland, Mark H.; Springett, Bradley R.; Freiberger, F.; Ribeiro Morais, Goreti; Loadman, Paul M.; Errington, R.J.; Smith, P.J.; Fukuda, M.; Gerardy-Schahn, R.; Patterson, Laurence H.; Shnyder, Steven D.; Falconer, Robert A. (2013) PLoS ONE. 8
Antitumor activity of a duocarmycin analogue rationalized to be metabolically activated by cytochrome P450 1A1 in human transitional cell carcinoma of the bladder

Sutherland, Mark H.; Gill, Jason H.; Loadman, Paul M.; Laye, Jonathan P.; Sheldrake, Helen M.; Illingworth, Nicola A.; Alandas, Mohammed N.; Cooper, Patricia A.; Searcey, M.; Pors, Klaus; Shnyder, Steven D.; Patterson, Laurence H. (2013)
Colon cancer-specific cytochrome P450 2W1 converts duocarmycin analogues into potent tumor cytotoxins

Travica, S.; Pors, Klaus; Loadman, Paul M.; Shnyder, Steven D.; Johansson, I.; Alandas, Mohammed N.; Sheldrake, Helen M.; Mkrtchian, S.; Patterson, Laurence H.; Ingelman-Sundberg, M. (2013)
Parallel RNA interference screens identify EGFR activation as an escape mechanism in FGFR3-mutant cancer

Herrera-Abreu, M.T.; Pearson, A.; Campbell, J.; Shnyder, Steven D.; Knowles, M.A.; Ashworth, A.; Turner, N.C. (2013)
Targeting of Hypoxia in AQ4N-treated Tumour Xenografts by MALDI-Ion Mobility Separation-Mass Spectrometry Imaging

Djidja, M-C.; Francese, S.; Claude, E.; Loadman, Paul M.; Sutton, Chris W.; Shnyder, Steven D.; Cooper, Patricia A.; Patterson, Laurence H.; Carolan, V.A.; Clench, M.R. (2013)
NCAM polysialylation during adherence transitions: Live cell monitoring using an antibody-mimetic EGFP-endosialidase and the viability dye DRAQ7

Smith P.;Furon E.;Wiltshire M.;Chappell S.;Patterson L.;Shnyder S.;Falconer R.;Errington R. (2013) Cytometry Part A. 83, 659-671.
Re-engineering of the Duocarmycin Structural Architecture Enables Bioprecursor Development Targeting CYP1A1 and CYP2W1 for Biological Activity

Sheldrake, Helen M.; Travica, S.; Johansson, I.; Loadman, Paul M.; Sutherland, Mark H.; Elsalem, Lina M.I.; Illingworth, Nicola A.; Cresswell, Alexander J.; Reuillon, Tristan; Shnyder, Steven D.; Mkrtchian, S.; Searcey, M.; Ingelman-Sundberg, M.; Patterson, Laurence H.; Pors, Klaus (2013)
Synthesis and biological evaluation of colchicine C-ring analogues tethered with aliphatic linkers suitable for prodrug derivatisation

Fournier-Dit-Chabert J.;Vinader V.;Santos A.;Redondo-Horcajo M.;Dreneau A.;Basak R.;Cosentino L.;Marston G.;Abdel-Rahman H.;Loadman P.;Shnyder S.;Díaz J.;Barasoain I.;Falconer R.;Pors K. (2012) Bioorganic and Medicinal Chemistry Letters. 22, 7693-7696.
Synthesis and biological evaluation of colchicine B-ring analogues tethered with halogenated benzyl moieties

Cosentino L.;Redondo-Horcajo M.;Zhao Y.;Santos A.;Chowdury K.;Vinader V.;Abdallah Q.;Abdel-Rahman H.;Fournier-Dit-Chabert J.;Shnyder S.;Loadman P.;Fang W.;Díaz J.;Barasoain I.;Burns P.;Pors K. (2012) Journal of Medicinal Chemistry. 55, 11062-11066.
Polysialyltransferase: A new target in metastatic cancer

Falconer R.;Errington R.;Shnyder S.;Smith P.;Patterson L. (2012) Current Cancer Drug Targets. 12, 925-939.
Use of the hollow fiber assay for the evaluation of DNA damaging agents

Veiga J.;Cooper P.;Pors K.;Patterson L.;Bibby M.;Shnyder S. (2011) Journal of Pharmacological and Toxicological Methods. 64, 226-232.
Anti-colorectal cancer activity of an organometallic osmium arene azopyridine complex

Shnyder S.;Fu Y.;Habtemariam A.;Van Rijt S.;Cooper P.;Loadman P.;Sadler P. (2011) MedChemComm. 2, 666-668.
Modification of the duocarmycin pharmacophore enables CYP1A1 targeting for biological activity

Pors, Klaus; Loadman, Paul M.; Shnyder, Steven D.; Sutherland, Mark H.; Sheldrake, Helen M.; Guino, M.; Kiakos, K.; Hartley, J.A.; Searcey, M.; Patterson, Laurence H. (2011)
Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo

Lamont, F.R.; Tomlinson, D.C.; Cooper, Patricia A.; Shnyder, Steven D.; Chester, J.D.; Knowles, M.A. (2011)
Adenovirus-mediated hypoxia-targeted gene therapy using HSV thymidine kinase and bacterial nitroreductase prodrug-activating genes in vitro and in vivo

Harvey T.;Hennig I.;Shnyder S.;Cooper P.;Ingram N.;Hall G.;Selby P.;Chester J. (2011) Cancer Gene Therapy. 18, 773-784.
An agarose spot chemotaxis assay for chemokine receptor antagonists

Vinader V.;Al-Saraireh Y.;Wiggins H.;Rappoport J.;Shnyder S.;Patterson L.;Afarinkia K. (2011) Journal of Pharmacological and Toxicological Methods. 64, 213-216.
The microtubule depolymerizing agent CYT997 causes extensive ablation of tumor vasculature in vivo

Burns, C.J.; Fantino, E.; Powell, A.K.; Shnyder, Steven D.; Cooper, Patricia A.; Nelson, S.; Christophi, C.; Malcontenti-Wilson, C.; Dubljevic, V.; Harte, M.F.; Joffe, M.; Phillips, I.D.; Segal, D.; Wilks, A.F.; Smith, G.D. (2011)
Retargeted adenoviral cancer gene therapy for tumour cells overexpressing epidermal growth factor receptor or urokinase-type plasminogen activator receptor

Harvey T.;Burdon D.;Steele L.;Ingram N.;Hall G.;Selby P.;Vile R.;Cooper P.;Shnyder S.;Chester J. (2010) Gene Therapy. 17, 1000-1010.
Development of a novel tumor-targeted vascular disrupting agent activated by Membrane-type Matrix Metalloproteinases (MT-MMPs)

Atkinson, Jennifer M.; Falconer, Robert A.; Edwards, D.R.; Pennington, C.J.; Siller, Catherine S.; Shnyder, Steven D.; Bibby, Michael C.; Patterson, Laurence H.; Loadman, Paul M.; Gill, Jason H. (2010)
Development of a novel tumor-targeted vascular disrupting agent activated by membrane-type matrix metalloproteinases

Atkinson J.;Falconer R.;Edwards D.;Pennington C.;Siller C.;Shnyder S.;Bibby M.;Patterson L.;Loadman P.;Gill J. (2010) Cancer Research. 70, 6902-6912.
Improved preparation and detection of cytochrome P450 isoforms using MS methods

Sutton C.;Sutherland M.;Shnyder S.;Patterson L. (2010) Proteomics. 10, 327-331.
Organometallic osmium arene complexes with potent cancer cell cytotoxicity

Fu Y.;Habtemariam A.;Pizarro A.;Van Rijt S.;Healey D.;Cooper P.;Shnyder S.;Clarkson G.;Sadler P. (2010) Journal of Medicinal Chemistry. 53, 8192-8196.
In vivo activation of the hypoxia-targeted cytotoxin AQ4N in human tumor xenograft.

Williams, K.J.; Albertella, M.R.; Fitzpatrick, B.; Loadman, Paul M.; Shnyder, Steven D.; Chinje, E.C.; Telfer, B.A.; Dunk, C.R.; Harris, P.A.; Stratford, I.J. (2009)
Fibroblast growth factor receptor 1 promotes proliferation and survival via activation of the mitogen-activated protein kinase pathway in bladder cancer

Tomlinson, D.C.; Lamont, F.R.; Shnyder, Steven D.; Knowles, M.A. (2009)
In vivo activation of the hypoxia-targeted cytotoxin AQ4N in human tumor xenografts

Williams K.;Albertella M.;Fitzpatrick B.;Loadman P.;Shnyder S.;Chinje E.;Telfer B.;Dunk C.;Harris P.;Stratford I. (2009) Molecular Cancer Therapeutics. 8, 3266-3275.
Development of a modified hollow fibre assay for studying agents targeting the tumour neovasculature.

Shnyder, Steven D.; Jubb, E.; Hasan, J.; Cooper, Patricia A.; Bibby, Michael C.; Jayson, G.C.; Pilarinou, E. (2009)
Use of the hollow fibre assay for studies of tumor neovasculature.

Shnyder S. (2009) Methods in molecular biology (Clifton, N.J.). 467, 331-342.
A cytotoxic diterpenoid from Croton membranaceus, the major constituent of anticancer herbal formulations used in Ghana

Bayor, M.T.;Ayim, J.S.K.;Marston, G.;Phillips, R.M.;Shnyder, S.D.;Wheelhouse, R.T.;Wright, C.W.; (2008) Natural product communications.
Guaianolide sesquiterpenes from Pulicaria crispa (Forssk.) Oliv.

Stavri, M.; Matthew, K.T.; Gordon, Andrew; Shnyder, Steven D.; Falconer, Robert A.; Gibbons, S. (2008) Phytochemistry. 69, 1915-1918.
Single-chain TNF, a TNF derivative with enhanced stability and antitumoral activity

Krippner-Heidenreich A.;Grunwald I.;Zimmermann G.;Kühnle M.;Gerspach J.;Sterns T.;Shnyder S.;Gill J.;Männel D.;Pfizenmaier K.;Scheurich P. (2008) Journal of Immunology. 180, 8176-8183.
Triplex profiling of functionally distinct chaperones (ERp29/PDI/BiP) reveals marked heterogeneity of the endoplasmic reticulum proteome in cancer

Shnyder S.;Mangum J.;Hubbard M. (2008) Journal of Proteome Research. 7, 3364-3372.
A cytotoxic diterpenoid from Croton membranaceus, the major constituent of anticancer herbal formulations in Ghana

Bayor, M.T.; Ayim, J.S.K.; Marston, G.; Phillips, Roger M.; Shnyder, Steven D.; Wheelhouse, Richard T.; Wright, Colin W. (2008)
Sodium pancratistatin 3,4-O-cyclic phosphate, a water-soluble synthetic derivative of pancratistatin, is highly effective in a human colon tumor model

Shnyder S.;Cooper P.;Millington N.;Gill J.;Bibby M. (2008) Journal of Natural Products. 71, 321-324.
Synthesis of cryptolepine analogues as potential bioreducible anticancer agents

Seville S.;Phillips R.;Shnyder S.;Wright C. (2007) Bioorganic and Medicinal Chemistry. 15, 6353-6360.
Auristatin PYE, a novel synthetic derivative of dolastatin 10, is highly effective in human colon tumour models.

Shnyder, Steven D.; Cooper, Patricia A.; Millington, Nicola J.; Pettit, G.R.; Bibby, Michael C. (2007)
The hollow fibre model - Facilitating anti-cancer pre-clinical pharmacodynamics and improving animal welfare

Suggitt M.;Cooper P.;Shnyder S.;Bibby M. (2006) International Journal of Oncology. 29, 1493-1499.
Synthesis of DNA-Directed Pyrrolidinyl and Piperidinyl Confined Alkylating Chloroalkylaminoanthraquinones: Potential for Development of Tumor-Selective N-Oxides

Patterson, Laurence H.; Pors, Klaus; Shnyder, Steven D.; Teesdale-Spittle, P.H.; Hartley, J.A.; Searcey, M.; Zloh, M. (2006)
Reducing the cost of screening novel agents using the hollow fibre assay

Shnyder S.;Cooper P.;Scally A.;Bibby M. (2006) Anticancer Research. 26, 2049-2052.
Design, synthesis, and biophysical and biological evaluation of a series of pyrrolobenzodiazepine-poly(N-methylpyrrole) conjugates

Wells G.;Martin C.;Howard P.;Sands Z.;Laughton C.;Tiberghien A.;Woo C.;Masterson L.;Stephenson M.;Hartley J.;Jenkins T.;Shnyder S.;Loadman P.;Waring M.;Thurston D. (2006) Journal of Medicinal Chemistry. 49, 5442-5461.
Development of a modified hollow fibre assay for studying agents targeting the tumour neovasculature

Shnyder S.;Hasan J.;Cooper P.;Pilarinou E.;Jubb E.;Jayson G.;Bibby M. (2005) Anticancer Research. 25, 1889-1894.
Heparin octasaccharides inhibit angiogenesis in vivo.

Hasan, J.; Shnyder, Steven D.; Clamp, A.R.; McGown, A.T.; Bicknell, R.; Presta, M.; Bibby, Michael C.; Double, John A.; Craig, S.; Leeming, D.; Stevenson, K.; Gallagher, J.T.; Jayson, G.C. (2005)
Synthesis of some cryptolepine analogues, assessment of their antimalarial and cytotoxic activities, and consideration of their antimalarial mode of action.

Wright, Colin W.; Onyeibor, O.; Phillips, Roger M.; Shnyder, Steven D.; Croft, S.L.; Dodson, Hilary I. (2005)
Preliminary pharmacokinetic and bioanalytical studies of SJG-136 (NSC 694501), a sequence-selective pyrrolobenzodiazepine dimer DNA-cross-linking agent.

Wilkinson, Gary P.; Taylor, James P.; Shnyder, Steven D.; Loadman, Paul M.; Cooper, Patricia A.; Howard, P.W.; Thurston, D.E.; Jenkins, Terence C. (2004)
Pharmacological and biological evaluation of a series of substituted 1,4 naphthoquinone bioreductive drugs.

Phillips, Roger M.; Loadman, Paul M.; Maitland, Derek J.; Shnyder, Steven D.; Jaffar, M.; Steans, Gillian; Cooper, Patricia A.; Race, Amanda D.; Patterson, A.V.; Stratford, I.J. (2004)
Secretory phospholipase A2as tumor-specific trigger for targeted delivery of a novel class of liposomal prodrug anticancer etherlipids

Jensen S.;Andresen T.;Davidsen J.;Høyrup P.;Shnyder S.;Bibby M.;Gill J.;Jørgensen K. (2004) Molecular Cancer Therapeutics. 3, 1451-1458.
Vinflunine Pierre Fabre/Bristol-Myers Squibb

Shnyder S. (2004) IDrugs : the investigational drugs journal. 7, 851-859.
Secretory phospholipase A2 as a tumor specific trigger for targeted delivery of a novel class of liposomal prodrug anticancer etherlipids

Gill, Jason H.; Bibby, Michael C.; Jensen, S.S.; Shnyder, Steven D. (2004)
Comparative Preclinical Pharmacokinetic and Metabolic Studies of the Combretastatin Prodrugs Combretastatin A4 Phosphate and A1 Phosphate

Kirwan, Ian G.; Loadman, Paul M.; Swaine, David J.; Anthoney, Alan; Pettit, G.R.; Lippert III, J.W.; Shnyder, Steven D.; Cooper, Patricia A.; Bibby, Michael C. (2004)
Vinflunine Potentiates the Activity of Cisplatin but Not 5-Fluorouracil in A Transplantable Murine Adenocarcinoma Model

Shnyder S.;Cooper P.;Gyselinck N.;Hill B.;Double J.;Bibby M. (2003) Anticancer Research. 23, 4815-4820.
Combretastatin A-1 phosphate potentiates the antitumour activity of cisplatin in a murine adenocarcinoma model

Shnyder S.;Cooper P.;Pettit G.;Lippert J.;Bibby M. (2003) Anticancer Research. 23, 1619-1623.
Combretastatin A-1 phosphate a novel tubulin-binding agent with in vivo anti vascular effects in experimental tumours

Holwell S.;Cooper P.;Grosios K.;Lippert J.;Pettit G.;Shnyder S.;Bibby M. (2002) Anticancer Research. 22, 707-711.
In vitro and in vivo activity of LS 4477 and LS 4559, novel analogues of the tubulin binder estramustine

Nicholson K.;Phillips R.;Shnyder S.;Bibby M. (2002) European Journal of Cancer. Part A. 38, 194-204.

RGD-binding integrins in head and neck cancers

Ahmedah H.;Patterson L.;Shnyder S.;Sheldrake H. (2017) Cancers.
Non-invasive molecular imaging for preclinical cancer therapeutic development

O'Farrell A.;Shnyder S.;Marston G.;Coletta P.;Gill J. (2013) British Journal of Pharmacology.
RGD-binding integrins in prostate cancer: Expression patterns and therapeutic prospects against bone metastasis

Sutherland M.;Gordon A.;Shnyder S.;Patterson L.;Sheldrake H. (2012) Cancers.
Quantitative angiogenesis assays in vivo - A review

Hasan J.;Shnyder S.;Bibby M.;Double J.;Bicknel R.;Jayson G. (2004) Angiogenesis.

Dr. Steven Shnyder

Associate Professor

Biography

Research

Professional activities

Committees (2)

Education (3)

Publications

Book chapter (1)

Conference publication (1)

Peer reviewed journal (78)

A cytotoxic diterpenoid from Croton membranaceus, the major constituent of anticancer herbal formulations used in Ghana

The hollow fibre model - Facilitating anti-cancer pre-clinical pharmacodynamics and improving animal welfare

Reducing the cost of screening novel agents using the hollow fibre assay

Development of a modified hollow fibre assay for studying agents targeting the tumour neovasculature

Secretory phospholipase A2as tumor-specific trigger for targeted delivery of a novel class of liposomal prodrug anticancer etherlipids

Vinflunine Pierre Fabre/Bristol-Myers Squibb

Vinflunine Potentiates the Activity of Cisplatin but Not 5-Fluorouracil in A Transplantable Murine Adenocarcinoma Model

Combretastatin A-1 phosphate potentiates the antitumour activity of cisplatin in a murine adenocarcinoma model

Combretastatin A-1 phosphate a novel tubulin-binding agent with in vivo anti vascular effects in experimental tumours

Reviews (4)